BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19866516)

  • 1. The Viracept-EMS case: impact and outlook.
    Walker VE; Casciano DA; Tweats DJ
    Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
    Müller L; Singer T
    Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
    Gocke E; Wall M
    Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
    Gocke E; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
    Gerber C; Toelle HG
    Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
    Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
    Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
    Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
    Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General 4-week toxicity study with EMS in the rat.
    Pfister T; Eichinger-Chapelon A
    Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
    Gocke E; Bürgin H; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
    Gocke E; Ballantyne M; Whitwell J; Müller L
    Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
    Gocke E; Müller L
    Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes are recommended in use of nelfinavir.
    Wilcox RD
    HIV Clin; 2008; 20(1):1, 4. PubMed ID: 18578034
    [No Abstract]   [Full Text] [Related]  

  • 16. Reichardt's dye and its reactions with the alkylating agents 4-chloro-1-butanol, ethyl methanesulfonate, 1-bromobutane and Fast Red B - a potentially useful reagent for the detection of genotoxic impurities in pharmaceuticals.
    Corrigan DK; Whitcombe MJ; McCrossen S; Piletsky S
    J Pharm Pharmacol; 2009 Apr; 61(4):533-7. PubMed ID: 19298702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
    Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
    Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats.
    Dobo KL; Fiedler RD; Gunther WC; Thiffeault CJ; Cammerer Z; Coffing SL; Shutsky T; Schuler M
    Mutat Res; 2011 Oct; 725(1-2):13-21. PubMed ID: 21729764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice.
    Cao X; Mittelstaedt RA; Pearce MG; Allen BC; Soeteman-Hernández LG; Johnson GE; Bigger CA; Heflich RH
    Environ Mol Mutagen; 2014 Jun; 55(5):385-99. PubMed ID: 24535894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens.
    Doak SH; Jenkins GJ; Johnson GE; Quick E; Parry EM; Parry JM
    Cancer Res; 2007 Apr; 67(8):3904-11. PubMed ID: 17440105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.